. Overview At Erasca, our name is our mission: to eras e ca ncer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Molecular alterations in RAS, the most frequently mutated oncogene, and the MAPK pathway, one of the most frequently altered signaling pathways in cancer, account for more than five million new patients diagnosed with cancer globally each year. Our compan...
Q2 FY2026 — expected 2026-08-11
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-12 | 2025-12-31 | 0001193125-26-104150 | EDGAR | 103K words |
| 2025-03-20 | 2024-12-31 | 0000950170-25-042682 | EDGAR | — |
| 2024-03-27 | 2023-12-31 | 0000950170-24-037193 | EDGAR | — |
| 2023-03-23 | 2022-12-31 | 0000950170-23-009496 | EDGAR | — |
| 2022-03-24 | 2021-12-31 | 0000950170-22-004557 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001193125-25-277625 | EDGAR | 27K words |
| 2025-08-12 | 2025-06-30 | 0001193125-25-178996 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0000950170-25-070418 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0000950170-24-125481 | EDGAR | — |
| 2024-08-12 | 2024-06-30 | 0000950170-24-095437 | EDGAR | — |
| 2024-05-08 | 2024-03-31 | 0000950170-24-055668 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0000950170-23-062094 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0000950170-23-041333 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0000950170-23-022282 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0000950170-22-023926 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0000950170-22-016907 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0000950170-22-009720 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-10 | 0001193125-26-342669 | EDGAR | — |
| 2026-07-14 | 0001193125-26-303357 | EDGAR | — |
| 2026-07-13 | 0001193125-26-302045 | EDGAR | — |
| 2026-03-12 | 0001193125-26-104105 | EDGAR | 3K words |
| 2026-01-29 | 0001193125-26-029467 | EDGAR | — |
| 2026-01-22 | 0001193125-26-019651 | EDGAR | — |
| 2026-01-20 | 0001193125-26-016556 | EDGAR | — |
| 2026-01-12 | 0001193125-26-009820 | EDGAR | — |
| 2025-11-12 | 0001193125-25-277571 | EDGAR | — |
| 2025-08-12 | 0001193125-25-178950 | EDGAR | — |
84 total filings indexed. 57 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001761918 |
| Ticker | ERAS |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.erasca.com |
| Listed | 2021-07-16 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ERAS (~200 tokens, structured JSON with cryptographic provenance)